Drug Trial Radar · NCT05531656
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Jun 28, 2023
Primary completion
May 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Cognition TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- National Institute on Aging (NIA); Alzheimer's Clinical Trials Consortium
- First posted
- Sep 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Conditions
- Early Alzheimer's Disease
Interventions
CT1812Drug
Study Drug
PlaceboDrug
Non-active study drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) scale.Time frame: 18 months
Locations
50 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Banner Alzheimer's Institute
Phoenix, Arizona
Banner Sun Health Research Institute
Sun City, Arizona
University of California
Irvine, California
Stanford University
Palo Alto, California
Sutter Institute for Medical Research
Sacramento, California
Yale University
New Haven, Connecticut
Georgetown University
Washington D.C., District of Columbia
Howard University
Washington D.C., District of Columbia
Brain Matters Research
Delray Beach, Florida
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida
Mayo Clinic,Jacksonville
Jacksonville, Florida
JEM Research Institute
Lake Worth, Florida
K2 Medical Research, LLC
Maitland, Florida
Advanced Clinical Research Network, Corp
Miami, Florida
Charter Research
Orlando, Florida
Headlands Research Orlando
Orlando, Florida
Brain Matters Research Stuart
Stuart, Florida
University of South Florida
Tampa, Florida
Conquest Research, LLC
Winter Park, Florida
Rush University Medical Center
Chicago, Illinois
Indiana University
Indianapolis, Indiana
Sanders-Brown Center on Aging
Lexington, Kentucky
John Hopkins University
Baltimore, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
Highlands Research Eastern MA
Plymouth, Massachusetts
University of Michigan, Ann Arbor
Ann Arbor, Michigan
Mayo Clinic, Rochester
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada
Mount Sinai School of Medicine
New York, New York
Columbia University Medical Center
New York, New York
University of Rochester Medical Center
Rochester, New York
Wake Forest University Health Sciences
Winston-Salem, North Carolina
Case Western Reserve University / University Hospitals
Beachwood, Ohio
Ohio State University
Columbus, Ohio
Central States Research, LLC
Tulsa, Oklahoma
Summit Headlands LLC
Portland, Oregon
Oregon Health & Science University
Portland, Oregon
Abington Neurological Associates
Abington, Pennsylvania
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.